Incidence, risk factors and outcomes of checkpoint inhibitor-induced liver injury: A 10-year real-world retrospective cohort study
Author:
Publisher
Elsevier BV
Subject
Gastroenterology,Hepatology,Immunology and Allergy,Internal Medicine
Reference58 articles.
1. Pembrolizumab versus ipilimumab in advanced melanoma;Robert;New Engl J Med,2015
2. Combined Nivolumab and ipilimumab or monotherapy in untreated melanoma;Larkin;N Engl J Med,2015
3. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma;Motzer;New Engl J Med,2018
4. Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors;De Martin;JHEP Rep,2020
5. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance;Martins;Nat Rev Clin Oncol,2019
Cited by 16 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Emerging role of immunotherapy for cancer as a major cause of drug-induced liver injury;Annals of Hepatology;2024-09
2. The role of the microbiome in immune checkpoint inhibitor colitis and hepatitis;Best Practice & Research Clinical Gastroenterology;2024-08
3. irLI or not irLI: That is the question;Journal of Hepatology;2024-07
4. The Epidemiology of Newly Recognized Causes of Drug-Induced Liver Injury: An Update;Pharmaceuticals;2024-04-18
5. Therapeutic inhibition of monocyte recruitment prevents checkpoint inhibitor-induced hepatitis;Journal for ImmunoTherapy of Cancer;2024-04
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3